Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

• Published in: BMC medicine Vol. 18; no. 1; pp. 87 - 14
• Main Authors: Zhou, Xiaoxiang, Yao, Zhuoran, Yang, Huaxia, Liang, Naixin, Zhang, Xuan, Zhang, Fengchun
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.04.2020; BioMed Central; BMC
• Subjects: Analysis; Antigens; Apoptosis; Bias; Cancer; Cancer patients; Cancer therapies; Care and treatment; Cell death; Complications and side effects; Confidence intervals; Cytotoxicity; Development and progression; Efficacy; Immune checkpoint inhibitors; Immune-related adverse events; Inhibitors; Lymphocytes; Lymphocytes T; Medical research; Melanoma; Meta-analysis; Patients; PD-1 protein; Software; Subgroups; Survival; Systematic review; Therapy; Efficacy; Immune checkpoint inhibitors; Immune-related adverse events; Cancer

A number of studies have reported an association between the occurrence of immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment with immune checkpoint inhibitors (ICIs), but the results remain controversial. Under the guidance of a predefined protocol and Pref...